SPECULATION AND RUMORS HAVE PUT THIS STOCK ON THE WATCHLIST FOR THE WEEKS TO COME, HAD A GOOD DAY ON FRIDAY WITH A 7%SPIKE ON GOOD VOLUME, WHICH MAY HAVE BEEN HAMPERED BY THE MARKET SENTIMENT. STOCK HAS SUFFERED RECENTLY FROM A SPLIT AND OFFERING SO WE AWAIT A POSITIVE CATALYST.
COMPANY PROFILE Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss.